Lupin has declared its fourth quarter results. Kamal K Sharma, MD, Lupin says, the company’s endeavour would be to grow around 25% year-on-year (YoY) on organic basis, unless it makes some inorganic moves that could be additive. “Our attempt has always been to improve on EBITDA margins by atleast 75 bps,” he adds.
first published: May 12, 2011 04:27 pm
A collection of the most-viewed Moneycontrol videos.
